Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06874725

Latent Tuberculosis in Type 2 Diabetes

Directly Observed Preventive Therapy (DOPT) for Latent Tuberculosis Infection Patients With Poorly Controlled Diabetes Mellitus

Status
Active Not Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
552 (actual)
Sponsor
Taichung Veterans General Hospital · Academic / Other
Sex
All
Age
45 Years
Healthy volunteers
Not accepted

Summary

The patients with poorly controlled DM underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated. The patients with LTBI received tuberculosis preventive therapy, 9 months of daily isoniazid (9H) or 3 months of weekly rifapentine plus isoniazid (3HP), administered by pulmonologists. The completion rates and inflammatory markers were also investigated.

Detailed description

Poor control of diabetes mellitus (DM) increases active tuberculosis (TB) risk. Understanding risk factors for latent TB infection (LTBI) in this population is crucial for policy making. Under a collaborative multidisciplinary team consisting of endocrinologists and pulmonologists, patients with poorly controlled DM were enrolled; these patients underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated. The patients with LTBI received tuberculosis preventive therapy, 9 months of daily isoniazid (9H) or 3 months of weekly rifapentine plus isoniazid (3HP), administered by pulmonologists. The completion rates and inflammatory markers were also investigated.

Conditions

Interventions

TypeNameDescription
DRUGRifapentine and Isoniazid for 3 monthstuberculosis preventive therapy (TPT) with 3 months of weekly rifapentine plus isoniazid (3HP)
DRUGIsoniazid (INH) daily for 9 monthstuberculosis preventive therapy (TPT) with 9 months of daily isoniazid (9H)

Timeline

Start date
2018-04-18
Primary completion
2024-04-30
Completion
2025-04-18
First posted
2025-03-13
Last updated
2025-03-13

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT06874725. Inclusion in this directory is not an endorsement.